Skip to main navigation

Menu

About RedHill

Company Profile
Management Team
Board of Directors
Advisory Board

Products

Commercial Products
- Donnatal®
- EnteraGam®
Development Pipeline

Investors

PRESS RELEASES
EVENTS & PRESENTATIONS
SEC FILINGS AND FINANCIAL INFORMATION
STOCK INFORMATION
ANALYST INFORMATION
CORPORATE GOVERNANCE
CONTACT US

News

2018
2017
2016
2015
2014
2013

Home // Investors

Investors

PRESS RELEASES

Summary Toggle RedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn’s Disease Study with RHB-104 to be Presented at UEG Week 2018

Oct 10, 2018

PDF Version
Summary Toggle RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference

Sep 20, 2018

PDF Version

CORPORATE PRESENTATION

RedHill Biopharma Corporate Presentation 1.8 MB

Oct 02, 2018

UPCOMING EVENTS & PRESENTATIONS

BIO-Europe 2018

Nov 5 - 7, 2018

Speaker:

Adi Frish

Senior VP Business Development and Licensing

Location:

Bella Center, Copenhagen, Denmark

View Additional Information

RedHill's presentation:

Date: Tuesday, Nov 6, 2018

Time: 16:15 CET

Room: B3 on level 0

Category: Gastrointestinal

BMO 2018 Prescriptions for Success Healthcare Conference

Dec 12, 2018

Location:

Mandarin Oriental, New York

FEATURED EVENTS

Webcast – RHB-104 positive Phase III top-line results for Crohn’s disease

Jul 30, 2018

Listen to webcast

RedHill Biopharma Webcast - RHB-104 Phase III Top-Line Results 665.3 KB

Webcast on RHB-104 for Crohn’s Disease

May 15, 2018
8:00 AM EDT

Listen to webcast

RedHill Biopharma - RHB-104 Crohn’s Disease Webcast (May 15 2018) 1.4 MB

Investor Relations

Press Releases
Events & Presentations
SEC Filings and Financial Information
Stock Information
Analyst Information
Corporate Governance
Contact Us

Investor Tools

Email Alerts Subscription
Download Library
Snapshot
RSS News Feeds
Print
Share

Facebook
Google
LinkedIn
Twitter
RSS

Home | Site menu | Privacy & Terms

Copyright © All Rights Reserved for RedHill Biopharma Ltd.
Created by Catom web design